Sorry, your browser doesn't support embedded videos.

 ISSUE 95 I June 2020

In association with

A cure

for a cost

Who foots the bill for vaccines and treatments developed during a pandemic?

Repurposing drugs for Covid-19

How safe are OTC painkillers?

Antitrust: Veeva vs. IQVIA

Where are the whistleblowers?

Creating a pharma playbook

2020: The year of the spin out?

05/27/2020 10:40:38
  • Home | A cure for a cost
  • In this issue
  • SHL Group Company Insight
  • Scandinavian Health
  • Contents
  • News
  • NSF
  • VEGA Company Insight
  • VEGA Australia
  • Covid-19 executive briefing by GlobalData
  • The value of real-world evidence during the Covid-19 outbreak
  • Covid-19: UK restricts parallel export of nearly 200 drugs, threatening its biopharma industry
  • Pharmaceutical professionals say employee safety and supply chain disruption are top Covid-19 concerns
  • AbbVie’s, Ascletis’ protease inhibitors spark skeptical outlook for repurposed activity in Covid-19
  • Phoenix
  • Phoenix Company Insight
  • The pharma industry briefing
  • No time to waste: repurposing drugs to tackle covid-19
  • How safe are simple painkillers?
  • Molnar Company Insight
  • Molnar-Institute
  • Modelling the human body: a game changer for drug testing?
  • Pandemic pricing: existing drugs and price gouging
  • Contract Pharmaceuticals Limited Canada
  • Pandemic pricing: novel treatments and vaccines
  • The dark side of anticoagulants: will a new approach shed light?
  • Zenatek
  • Finding a cure for HIV with ViiV Healthcare and UNC-Chapel Hill
  • Disputing the facts: is the legal battle between Veeva and IQVIA an antitrust issue
  • Nelson Labs
  • Could nanoparticles unlock the pharmaceutical benefits of turmeric?
  • Why aren’t more companies automating PV data capture?
  • Modality Solutions
  • Deals in brief powered by GlobalData
  • The key list powered by GlobalData
  • Butterworth
  • Global markets and indices powered by GlobalData
  • Macro-economic indicators (1 of 2) powered by GlobalData
  • Macro-economic indicators (2 of 2) powered by GlobalData
  • Mimotopes
  • Events
  • Next issue